Nuraleve Receives CE Mark Approval

Nuraleve is proud to announce that on August 10th 2015, our Neurostimulator has been approved for the following indications in the European market:

  • Chronic Pain
  • Addiction Reduction (including smoking)
  • Depression
  • Post-stroke Rehabilitation
  • Cognitive deficits (including those related to decision making)

This CE mark approval expands the markets where Nuraleve products are available, and represents a major milestone in the go-to-market strategy set out by the board of directors in 2013.